What is the recommended dosing regimen, contraindications, and monitoring for Menostar (human menopausal gonadotropin) in ovarian stimulation for assisted reproductive techniques?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Menostar: Critical Product Identification Error

Menostar is NOT human menopausal gonadotropin (hMG) for ovarian stimulation—it is an estradiol transdermal patch (14 mcg/day) indicated solely for prevention of postmenopausal osteoporosis. This is a fundamental medication safety issue that must be clarified immediately 1.

What Menostar Actually Is

Menostar is a low-dose estradiol transdermal system delivering 14 mcg of estradiol per day via a 3.25 cm² patch containing 1 mg total estradiol 1.

Approved Indication

  • Prevention of postmenopausal osteoporosis only 1
  • Should only be considered for women at significant risk of osteoporosis when non-estrogen medications have been evaluated first 1

Dosing Regimen

  • Apply one patch to clean, dry area of lower abdomen or upper buttock once weekly 1
  • Rotate application sites with minimum 1-week interval between same site 1
  • Do NOT apply to or near breasts 1
  • Use lowest effective dose for shortest duration consistent with treatment goals 1

Contraindications (Absolute)

  • Undiagnosed abnormal genital bleeding 1
  • Breast cancer (current or history) 1
  • Estrogen-dependent neoplasia 1
  • Active or history of DVT/PE 1
  • Active or history of arterial thromboembolic disease (stroke, MI) 1
  • Known hypersensitivity/anaphylaxis/angioedema to Menostar 1
  • Hepatic impairment or disease 1
  • Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders 1

Critical Safety Warnings

Cardiovascular risks: Estrogen-alone therapy increases risk of stroke and DVT. Immediately discontinue if these occur or are suspected 1.

Endometrial cancer risk: Women with intact uterus generally require progestogen addition to reduce endometrial cancer risk. Women without uterus do not need progestogen unless they have history of endometriosis 1.

Monitoring Requirements

  • Periodic reevaluation to determine if treatment remains necessary 1
  • Manage cardiovascular risk factors (hypertension, diabetes, tobacco use, hypercholesterolemia, obesity) 1
  • Manage VTE risk factors (personal/family history of VTE, obesity, systemic lupus erythematosus) 1

If You Need hMG for Ovarian Stimulation

For actual ovarian stimulation in IVF/ICSI, hMG is equally recommended to recombinant FSH (r-hFSH) with a conventional starting dose of 150-225 IU 2. The 2026 ESHRE guidelines provide strong evidence that hMG and r-hFSH have equivalent efficacy for ovarian stimulation 2.

Key Points for hMG in Ovarian Stimulation

  • Conventional gonadotropin dosing: 150-225 IU 2
  • Combining r-hFSH with hMG (either from start or mid-phase) is probably NOT recommended over using either alone in normal and low responders 2
  • In women with predicted high response using short GnRH antagonist protocols, hMG may reduce OHSS compared with rFSH 3

This distinction between Menostar (estrogen patch) and hMG (gonadotropin for fertility) is critical for patient safety.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.